Alternative Models of Financing Medical Innovation
Rebecca Wolf, Daniel Rosenholtz, Ray Zulueta, and Justin Carlson, October 21, 2009
Problematic Provisions in African Anticounterfeiting Legislation
Dan Rosenholt, September 24, 2009
CAFTA's Effect on Generic Drugs in Guatemala (New Paper by Ellen Shaffer and Joe Brenner)
Mike Palmedo - August 26, 2009
Access to Medicines
| ||ACCESS TO MEDICINE LEGAL EDUCATION INITIATIVE |
Working with the Open Society Institute and the UN Development Programme, PIJIP has organized numerous short courses and workshops in Pretoria, South Africa, and Kiev, Ukraine. We work with local academics and leading advocates to train students, pracitioners, elected officials, and health advocates in the use of IP flexibilities to guarantee access to generic medicines.
State governments use a system of open forumularies known as preferred drug lists in Medicaid and other programs that purchase pharmaceuticals in order to control costs. The safety, efficacy, and cost effectiveness of new treatments are compared to existing ones, and the best drugs are included in the PDL. Federal trade policy seeks to limit this type of evidence-based pricing.
The Trans Pacific Partnership Agreement (TPP) is a plurilateral free trade agreement that is currently being negotiated among Australia, New Zealand, Singapore, Brunei Darussalam, Chile, Peru, Vietnam, and the United States. Negotiators are drafting text over the summer of 2010, which they hope to table in October.
| US PRESCRIPTION POLICIES AND ACCESS TO MEDICINES|
State governments have begun to pass laws restricting data mining – the process by which pharmaceutical firms purchase prescribing records to hone their marketing tospecific doctors. Data mining grants pharmaceutical marketers undue influence on prescribing decisions, raises overall healthcare costs for consumers and bulk purchasers, and violates both patient and prescriber privacy.
PIJIP is creating a new project to analyze US bilateral trade pressures against countries perceived to have inadequate intellectual property protection. The US Trade Representative annually outlines its grievances against other countries in the Special 301 Report, which is highly influenced by industries seeking higher levels of copyright, patent, trademark, and other IP protection.
High medicine prices and the lack of access they create have been defended as necessary to support further pharmaceutical research and development. Industry proposals for increased access to medicines in developing countries have relied on the maintenance of high prices in developed countries. However, new frameworks for R&D funding would separate the market for finished pharmaceutical products and the scientific work needed for innovation.
Thai Compulsory Licensing Dispute | Hepatitis C and Pegylated Interferon | Korea-US FTA Provisions on Pharmaceutical Reimbursements| Brazilain Compulsory Licensing Dispute | Access to Second Generation Antiretrovirals | TRIPS-Plus Intellectual Property Rules in Bilateral FTAs | Amendments to the Indian Patents Act | Canadian Export of Generic Medicines Produced Under Compulsory License
Attribution for photos posted on flickr.com under a creative commons license: Photo of Korean FTA protester taken from Huffington Post blog by James Love. Photo of round doorway by Erin Watson. Photo of doctor writing prescription by Happy Via. Photo of pills against a blue background by Darren Hester.